التفاصيل البيبلوغرافية
| العنوان: |
Pretreatment serum lactate dehydrogenase is an independent prognostic factor for patients receiving neoadjuvant chemotherapy for locally advanced cervical cancer. |
| المؤلفون: |
Li, Jing, Wu, Miao‐Fang, Lu, Huai‐Wu, Chen, Qing, Lin, Zhong‐Qiu, Wang, Li‐Juan |
| المصدر: |
Cancer Medicine; Aug2016, Vol. 5 Issue 8, p1863-1872, 10p |
| مصطلحات موضوعية: |
CERVICAL cancer treatment, PATHOPHYSIOLOGY of anoxemia, LACTATE dehydrogenase, CANCER chemotherapy, CANCER prognosis |
| مستخلص: |
For locally advanced cervical cancer ( LACC), hypoxia is a characteristic property. This study aimed to investigate whether baseline lactic dehydrogenase ( LDH) level, which is a marker of hypoxia, had clinical value in determining neoadjuvant chemotherapy ( NACT) response and prognosis for LACC patients. The study cohort included 418 patients with a median follow-up of 37.5 months. Cox proportional hazards models were used to assess the prognostic value of baseline LDH levels. Multivariate logistic regression analysis was performed to identify independent predictors of complete response after NACT. Backward stepwise selection with the Akaike information criterion was used to identify factors that could be entered into the multivariate regression model. Compared with patients with LDH levels <252.0 μ/L, patients with LDH levels ≥252.0 μ/L were more likely to have an elevated level of squamous cell carcinoma antigen, lymphatic vascular space involvement, lymph node metastasis, and positive parametrium and achieved lower complete remission rates. Baseline LDH levels ≥252.0 μ/L was an independent prognosticator for recurrence-free survival (adjusted hazard ratio [ HR], 3.56; 95% confidence interval [ CI] 2.22-5.69; P < 0.0001) and cancer-specific survival (adjusted HR, 3.08; 95% CI, 1.89-5.01; P < 0.0001). The predictive value of baseline LDH value remained significant in the subgroup analysis. LDH level ≥252.0 μ/L was identified as an independent predictor of complete remission after NACT (adjusted odds ratio [ OR], 0.29; 95% CI, 0.15-0.58; P < 0.0001). Baseline LDH ≥252.0 μ/L is an independent prognostic predictor for patients receiving neoadjuvant chemotherapy for LACC. It helps distinguish patients with different prognosis and select patients who are more likely to benefit from NACT. [ABSTRACT FROM AUTHOR] |
|
Copyright of Cancer Medicine is the property of Wiley-Blackwell and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| قاعدة البيانات: |
Complementary Index |
Full Text Finder